Dr. Wilfried Stücker
Geschäftsführung und Leitung der IOZK Arbeitsgruppe
Geschäftsführung und Leitung der IOZK Arbeitsgruppe
„Das Leben der Krebspatienten zu verlängern und Ihnen eine schonende Therapie anzubieten, dafür setzen wir uns am IOZK mit unserer Expertise ein.“
Dr. Wilfried Stücker
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)Poster presentation at the annual meeting of the Association for Cancer Immunotherapy
/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)Poster presentation at the International Symposium on Pediatric Neuro-Oncology
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
/in International Publications, IOZK Veröffentlichungen /von 2021-07-04 / Cancer Immunol Immunother 2021 Jul;Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in International Publications, IOZK Veröffentlichungen /von 2020-07-23 / Biomedicines 2020 Jul;8(8)Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-05-19 / Medicines (Basel) 2020 May;7(5)Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
/in Breast Cancer, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2015-05-28 / Immunotherapy 2015;7(8):855-60Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
/in Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus, Prostate Cancer /von 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406